Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival [0.03%]
Y Wang,D Drubay,S F Jonas et al.
Y Wang et al.
Background: Stromal tumor infiltrating lymphocytes (sTILs) are a strong prognostic marker in triple-negative breast cancer (TNBC) patients. We aimed to incorporate sTILs into the PREDICT model for women with early-stage T...
Colorectal cancer detection using non-contrast CT and deep learning: a multicenter and international cohort study [0.03%]
X Chen,M Y Qiu,J P Zhang et al.
X Chen et al.
Background: Colorectal cancer (CRC) is a leading cause of cancer deaths, with early screening vital to reduce mortality. While methods like colonoscopy and CT colonography are available, they face challenges such as bowel...
Re-Evaluating Antibody-Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation [0.03%]
R Colombo,S Seredick,S D Barnscher et al.
R Colombo et al.
Antibody-drug conjugates (ADCs) have emerged as an important class of anticancer therapeutics. Their highly modular design offers multiple opportunities to refine their properties and improve clinical performance by tuning individual compon...
J C Hassel,A Arance,M S Carlino et al.
J C Hassel et al.
Background: IO102-IO103, an investigational, immune-modulatory cancer vaccine, targets both tumor cells and immune-suppressive cells within the tumor microenvironment through activation and expansion of T cells against in...
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914) [0.03%]
O Gluz,U Nitz,M Christgen et al.
O Gluz et al.
Background: Low Ki67 after short preoperative endocrine treatment (ET) indicates a favorable prognosis in HR+/HER2- early breast cancer (eBC). We investigated predictors of ET-response in the WSG ADAPT-HR+/HER2- and ADAPT...
DART (NCI/SWOG S1609): Comprehensive Final Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare Cancers [0.03%]
S P Patel,M Othus,Y K Chae et al.
S P Patel et al.
Background: We summarize final results of the NCI/SWOG S1609 trial, whose objective was to evaluate efficacy signals across 53 refractory rare cancer cohorts treated with dual CTLA-4 and PD-1 inhibition. ...
A Simple Plan: Chemotherapy-Sparing Approaches to Early Stage and Regional Seminoma and Non-Seminoma [0.03%]
L Nappi,A Thor,T Tandstad et al.
L Nappi et al.
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [0.03%]
C Cremolini,M Chalabi,E Elez et al.
C Cremolini et al.
Genomic Determinants of Response to Alpelisib Plus Fulvestrant in the SOLAR-1 Trial [0.03%]
SOLAR-1试验中阿培利塞联合氟维司群治疗的基因组决定因素
D Juric,H S Rugo,A Reising et al.
D Juric et al.
Background: Approximately 40% of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) have PIK3CA alterations, which contributes to endocri...
The Curious Incident of the T-DXd Arm Killed at (DESTINY-Breast) Eleven O'Clock: Statistical Concerns [0.03%]
T-DXd臂在 DESTINY-Breast十一點被杀死：统计学担忧
Armando Orlandi
Armando Orlandi